ESMO: Merck’s Keytruda tames stage 2 melanoma, reducing cancer recurrence in postsurgery use
Source: Fierce Pharma, September 2021
Stage 3 melanoma was the first cancer area to have an FDA-approved immunotherapy to prevent disease from returning after surgery. Now, Merck & Co.’s Keytruda has shown it can do the same in stage 2 skin cancer.
